- •Abbreviations
- •1 Overview of Antimicrobial Therapy
- •Factors in Antibiotic Selection
- •Factors in Antibiotic Dosing
- •Microbiology and Susceptibility Testing
- •PK/PD and Other Considerations in Antimicrobial Therapy
- •Antibiotic Failure
- •Pitfalls in Antibiotic Prescribing
- •References and Suggested Readings
- •2 Empiric Therapy Based on Clinical Syndrome
- •Empiric Therapy of CNS Infections
- •Empiric Therapy of HEENT Infections
- •Empiric Therapy of Lower Respiratory Tract Infections
- •Empiric Therapy of GI Tract Infections
- •Empiric Therapy of Genitourinary Tract Infections
- •Empiric Therapy of Sexually Transmitted Diseases
- •Empiric Therapy of Bone and Joint Infections
- •Empiric Therapy of Skin and Soft Tissue Infections
- •Sepsis/Septic Shock
- •Febrile Neutropenia
- •Transplant Infections
- •Toxin-Mediated Infectious Diseases
- •Bioterrorist Agents
- •References and Suggested Readings
- •Gram Stain Characteristics of Isolates
- •Parasites, Fungi, Unusual Organisms in Blood
- •Parasites, Fungi, Unusual Organisms in CSF/Brain
- •Parasites, Fungi, Unusual Organisms in Lungs
- •Parasites, Fungi, Unusual Organisms in Heart
- •Parasites, Fungi, Unusual Organisms in the Liver
- •References and Suggested Readings
- •5 HIV Infection
- •HIV Infection Overview
- •Stages of HIV Infection
- •Acute (Primary) HIV Infection
- •Initial Assessment of HIV Infection
- •Indications for Treatment of HIV Infection
- •Antiretroviral Treatment
- •Treatment of Other Opportunistic Infections in HIV
- •HIV Coinfections (HBV/HCV)
- •References and Suggested Readings
- •6 Prophylaxis and Immunizations
- •Surgical Prophylaxis
- •Post-Exposure Prophylaxis
- •Chronic Medical Prophylaxis
- •Endocarditis Prophylaxis
- •Travel Prophylaxis
- •Tetanus Prophylaxis
- •Immunizations
- •References and Suggested Readings
- •Empiric Therapy of CNS Infections
- •Empiric Therapy of HEENT Infections
- •Empiric Therapy of Lower Respiratory Tract Infections
- •Empiric Therapy of Vascular Infections
- •Empiric Therapy of Gastrointestinal Infections
- •Empiric Therapy of Bone and Joint Infections
- •Empiric Therapy of Skin and Soft Tissue Infections
- •Common Pediatric Antimicrobial Drugs
- •References and Suggested Readings
- •8 Chest X-Ray Atlas
- •References and Suggested Readings
- •9 Infectious Disease Differential Diagnosis
- •11 Antimicrobial Drug Summaries
- •Appendix
- •Malaria in Adults (United States)
- •Malaria in Children (United States)
- •Index
358 |
A n t i b i o t i c E s s e n t i a l s |
POST-EXPOSURE PROPHYLAXIS
Some infectious diseases can be prevented by post-exposure prophylaxis (PEP).. To be maximally effective, PEP should be administered within 24 hours of the exposure, since the effectiveness of prophylaxis > 24 hours after exposure decreases.. PEP is usually reserved for persons with close/ intimate contact with an infected individual.. Casual contact does not warrant PEP..
Table 6.3. Post-Exposure Prophylaxis
|
Usual |
Preferred |
Alternate |
|
Exposure |
Organisms |
Prophylaxis |
Prophylaxis |
Comments |
|
|
|
|
|
Meningitis |
N.. |
Any quinolone |
Minocycline |
Must be administered |
|
meningitidis |
(PO) × 1 dose |
100 mg (PO) |
within 24 hours of close |
|
|
|
q12h × 2 days |
face-to-face exposure to |
|
|
|
or |
be effective.. Otherwise, |
|
|
|
Rifampin 600 mg |
observe and treat if |
|
|
|
(PO) q12h × 2 |
infection develops.. |
|
|
|
days |
|
|
|
|
|
|
|
H.. influenzae |
Rifampin |
Any quinolone |
Must be administered within |
|
|
600 mg (PO) |
(PO) × 3 days |
24 hours of close face-to-face |
|
|
q24h × 3 days |
|
exposure to be effective.. |
|
|
|
|
H.. influenzae requires 3 days |
|
|
|
|
of prophylaxis.. |
|
|
|
|
|
Influenza |
Influenza |
Oseltamivir |
Rimantadine |
Give to non-immunized |
|
A or B |
(Tamiflu) 75 mg |
100 mg (PO) |
contacts and high-risk |
|
|
(PO) q24h for |
q12h* for |
contacts even if |
|
|
duration of |
duration of |
immunized.. Begin at onset |
|
|
outbreak (or |
outbreak (or at |
of outbreak or within |
|
|
at least 7 days |
least 7–10 days |
3 days of close contact |
|
|
after close |
after close |
to an infected person.. |
|
|
contact to |
contact to |
Oseltamivir is active |
|
|
an infected |
infected person) |
against both influenza A |
|
|
person)..§ |
or |
and B; rimantadine and |
|
|
|
Amantidine 200 mg |
amantadine are only active |
|
|
|
(PO) q24h† |
against influenza A.. |
|
|
|
for 7–10 days or |
Oseltamivir may be |
|
|
|
outbreak |
ineffective due to |
|
|
|
|
resistance.. |
|
|
|
|
|
§ Dose for CrCl > 30–60 mL/min = 30 mg (PO) q24h; for CrCl >10–30 mL/min = 30 mg (PO) q48h..
|
Chapter 6. Prophylaxis and Immunizations |
359 |
||||
Table 6.3. Post-Exposure Prophylaxis (cont’d) |
|
|
|
|||
|
|
|
|
|
|
|
|
Usual |
Preferred |
Alternate |
|
||
Exposure |
Organisms |
Prophylaxis |
Prophylaxis |
Comments |
||
|
|
|
|
|
|
|
Avian |
Influenza A |
Oseltamivir |
|
Rimantadine |
|
Oseltamivir may be |
influenza |
(H5N1) |
(as for viral |
|
or |
|
ineffective due to |
|
|
influenza, |
|
Amantadine† (as |
|
resistance.. |
|
|
above) |
|
for viral influenza, |
|
|
|
|
|
|
above) |
|
|
|
|
|
|
|
|
|
Swine |
Influenza A |
Oseltamavir |
|
None |
|
Amantadine/rimantadine |
influenza |
(H1N1) |
above (as for |
|
|
|
ineffective |
|
|
viral influenza, |
|
|
|
Continue PEP for swine |
|
|
above) |
|
|
|
influenza (H1N1) ×10 days |
|
|
|
|
|
|
post-close exposure..‡ |
Pertussis |
B.. pertussis |
Erythromycin |
|
TMP–SMX 1 |
|
Administer as soon as |
|
|
500 mg (PO) |
|
SS tablet (PO) |
|
possible after exposure.. |
|
|
q6h × 2 weeks |
|
q12h × 2 weeks |
|
Effectiveness is greatly |
|
|
|
|
or |
|
reduced after 24 hours.. |
|
|
|
|
Levofloxacin |
|
|
|
|
|
|
500 mg (PO) |
|
|
|
|
|
|
q24h × 2 weeks |
|
|
|
|
|
|
|
|
|
Diphtheria |
C.. diphtheriae |
Erythromycin |
|
Azithromycin 500 |
|
Administer as soon as |
|
|
500 mg (PO) |
|
mg (PO) q24h × |
|
possible after exposure.. |
|
|
q6h × 1 week |
|
3 days |
|
Effectiveness is greatly |
|
|
or |
|
|
|
reduced after 24 hours.. |
|
|
Benzathine |
|
|
|
|
|
|
penicillin 1..2 mu |
|
|
|
|
|
|
(IM) × 1 dose |
|
|
|
|
|
|
|
|
|
|
|
TB |
M.. |
Rifampin 600 |
|
Rifapentine |
|
For INH, monitor SGOT/ |
|
tuberculosis |
mg (PO) q24h × |
|
900 mg (PO) |
|
SGPT weekly × 4, then |
|
|
4 months§ |
|
q week |
|
monthly.. Mild elevations |
|
|
or |
|
plus |
|
are common and resolve |
|
|
INH 300 mg |
|
INH 900 mg (PO) q |
|
spontaneously.. D/C INH |
|
|
(PO) q24h × |
|
week × 3 months |
|
if SGOT/SGPT levels ≥ 5 × |
|
|
9 months |
|
(D..O..T..) |
|
normal.. |
|
|
|
|
|
|
|
*For elderly, severe liver dysfunction, or CrCl < 10 cc/min, give 100 mg (PO) q24h..
†For age ≥ 65 years, give 100 mg (PO) q24h. . For renal dysfunction, give 200 mg (PO) load followed
by 100 mg q24h (CrCl 30–50 ml/min), 100 mg q48h (CrCl 15–29 ml/min), or 200 mg weekly (CrCl < 15 ml/min)..
‡Pediatric prophylaxis: < 15 kg: 30 mg PO qd for 10 days, > 15-24 kg: 45 mg PO qd for 10 days, 24-40 kg: 60 mg PO qd for 10 days, > 40 kg: same as adults..
§ INH preferred if patient uses contact lens, has HIV, or is taking medications that may interact with rifampin.
360 |
|
A n t i b i o t i c |
E s s e n t i a l s |
|
Table 6.3. Post-Exposure Prophylaxis (cont’d) |
|
|||
|
|
|
|
|
|
Usual |
Preferred |
Alternate |
|
Exposure |
Organisms |
Prophylaxis |
Prophylaxis |
Comments |
|
|
|
|
|
Gonorrhea |
N.. |
Ceftriaxone |
Spectinomycin 2 |
Administer as soon as |
(GC) |
gonorrhoeae |
125 mg (IM) × |
gm (IM) × 1 dose |
possible after sexual |
|
|
1 dose |
or |
exposure (≤ 72 hours).. |
|
|
|
Any oral |
Ceftriaxone also treats |
|
|
|
quinolone × |
incubating syphilis.. |
|
|
|
1 dose |
|
|
|
|
|
|
Syphilis |
T.. pallidum |
Benzathine |
Doxycycline |
Administer as soon as |
|
|
penicillin |
100 mg (PO) |
possible after sexual |
|
|
2..4 mu (IM) × 1 |
q12h × 1 week |
exposure.. Obtain HIV |
|
|
dose |
|
serology.. |
|
|
|
|
|
Chancroid |
H.. ducreyi |
Ceftriaxone |
Azithromycin 1 |
Administer as soon as |
|
|
250 mg (IM) × |
gm (PO) × 1 dose |
possible after sexual |
|
|
1 dose |
or |
exposure.. Obtain HIV and |
|
|
|
Any oral |
syphilis serologies.. |
|
|
|
quinolone × |
|
|
|
|
3 days |
|
|
|
|
|
|
Non- |
C.. trachomatis |
Azithromycin |
Any oral |
Administer as soon as |
gonococcal |
U.. urealyticum |
1 gm (PO) × |
quinolone × |
possible after sexual |
urethritis |
M.. genitalium |
1 dose |
1 week |
exposure.. Also test for |
(NGU) |
|
or |
|
gonorrhea/Ureaplasma.. |
|
|
Doxycycline 100 |
|
|
|
|
mg (PO) q12h × |
|
|
|
|
1 week |
|
|
|
|
|
|
|
Varicella |
VZV |
Preferred: For exposure < 72 hours, |
Administer as soon as |
|
(chicken-pox) |
|
give varicella-zoster immune |
possible after exposure |
|
|
|
globulin (VZIG) 625 mcg (IM) × 1 |
(≤ 72 hours).. Varicella |
|
|
|
dose to immuno-compromised |
vaccine is a live |
|
|
|
hosts and pregnant women (esp.. |
attenuated vaccine and |
|
|
|
with respiratory conditions).. For |
should not be given to |
|
|
|
others or exposure > 72 hours, |
immunocompromised |
|
|
|
consider acyclovir 800 mg (PO) 5x/ |
or pregnant patients.. If |
|
|
|
day × 5–10 days |
|
varicella develops, start |
|
|
Alternate: Varicella vaccine 0..5 mL |
acyclovir treatment |
|
|
|
immediately.. |
||
|
|
(SC) × 1 dose.. Repeat in 4 weeks |
||
|
|
|
||
|
|
|
|
|
|
Chapter 6. Prophylaxis and Immunizations |
361 |
||||
Table 6.3. Post-Exposure Prophylaxis (cont’d) |
|
|
|
|||
|
|
|
|
|
|
|
|
Usual |
Preferred |
Alternate |
|
||
Exposure |
Organisms |
Prophylaxis |
Prophylaxis |
Comments |
||
|
|
|
|
|
|
|
Hepatitis A |
Hepatitis A |
HAV vaccine |
|
Immune serum |
|
Give HAV vaccine alone |
(HAV) |
virus |
1 mL (IM) × 1 |
|
globulin (IG) 0..02 |
|
if within 14 days after |
|
|
dose |
|
mL/kg (IM) × 1 |
|
exposure.. |
|
|
|
|
dose |
|
|
|
|
|
|
|
|
|
Hepatitis B |
Hepatitis B |
Unvaccinated |
|
Previously vaccinated |
||
(HBV) |
virus |
Hepatitis B |
|
Known responder (anti-HBsAg antibody levels |
||
|
|
immune |
|
≥ 10 IU/mL): No treatment.. |
||
|
|
globulin (HBIG) |
|
Known non-responder (anti-HBsAg antibody |
||
|
|
0..06 mL/kg (IM) |
|
|||
|
|
|
levels < 10 IU/mL): Treat as if unvaccinated.. |
|||
|
|
× 1 dose |
|
|||
|
|
|
|
|
|
|
|
|
plus |
|
Antibody status unknown: Obtain HBsAg antibody |
||
|
|
HBV vaccine (40 |
|
levels to determine immunity status.. If testing is |
||
|
|
mcg HBsAg/mL) |
|
not possible or results are not available within 24 |
||
|
|
deep deltoid (IM) |
|
hours of exposure, give HBIG plus 1 dose of HBV |
||
|
|
at 0, 1, 6 months |
|
vaccine (booster).. |
|
|
|
|
(can use |
|
|
|
|
|
|
10-mcg dose in |
|
|
|
|
|
|
healthy adults |
|
|
|
|
|
|
<40 years) |
|
|
|
|
|
|
|
|
|
|
|
Hepatitis C |
Hepatitis C |
None |
|
|
|
|
(HCV) |
virus |
|
|
|
|
|
|
|
|
|
|
||
Rocky |
R.. rickettsia |
Doxycycline 100 |
|
Any oral |
|
Administer prophylaxis |
Mountain |
|
mg (PO) q12h × |
|
quinolone × 1 |
|
after removal of |
spotted fever |
|
1 week |
|
week |
|
Dermacentor tick.. |
|
|
|
|
|
|
|
Lyme disease |
B.. burgdorferi |
Doxycycline |
|
Amoxicillin* 1 gm |
|
If tick is in place ≥ 72 hours |
|
|
200 mg (PO) × |
|
(PO) q8h × |
|
or is grossly engorged, |
|
|
1 dose |
|
3 days or |
|
prophylaxis may be given |
|
|
|
|
Any oral 1st gen.. |
|
after tick is removed.. |
|
|
|
|
cephalosporin* × |
Otherwise, prophylaxis is |
|
|
|
|
|
3 days |
|
usually not recommended.. |
|
|
|
|
or |
|
|
|
|
|
|
Azithromycin* |
|
|
|
|
|
|
500 mg (PO) |
|
|
|
|
|
|
q24h × 3 days |
|
|
|
|
|
|
|
|
|
HDCV = human diploid cell vaccine, HRIG = human rabies immune globulin, PCEC = purified chick embryo cells, RVA = rabies vaccine absorbed.
*All or as much of the full dose of HRIG should be injected into the wound, and the remaining vaccine should be injected IM into the deltoid.. Do not give HRIG at the same site or through the same syringe with PCEC, RVA, or HDCV..
362 |
|
A n t i b i o t i c |
E s s e n t i a l s |
|
Table 6.3. Post-Exposure Prophylaxis (cont’d) |
|
|||
|
|
|
|
|
|
Usual |
Preferred |
Alternate |
|
Exposure |
Organisms |
Prophylaxis |
Prophylaxis |
Comments |
*Although experience is limited, single-dose prophylaxis with these agents is probably also effective..
Zoonotic |
B.. anthracis |
Doxycycline 100 |
Any oral |
Continued for the duration |
diseases |
Y.. pestis |
mg (PO) q12h |
quinolone for |
of a naturally-acquired |
(plague, |
|
for duration of |
duration of |
exposure/outbreak.. See p.. |
anthrax) |
|
exposure |
exposure |
363 for bioterrorist plague/ |
|
|
|
|
anthrax recommendations.. |
|
|
|
|
|
Rabies |
Rabies virus |
No Previous |
Previous |
Following unprovoked |
|
|
Immunization |
Immunization |
or suspicious dog or cat |
|
|
HRIG 20 IU/kg* |
PCEC 1 mL (IM) in |
bite, immediately begin |
|
|
plus either |
deltoid on days 0 |
prophylaxis if animal |
|
|
PCEC 1 mL (IM) |
and 3 |
develops rabies during a |
|
|
in deltoid |
or |
10-day observation period.. |
|
|
or |
RVA 1 mL (IM) in |
If dog or cat is suspected |
|
|
RVA 1 mL (IM) in |
deltoid on days 0 |
of being rabid, begin |
|
|
deltoid |
and 3 |
vaccination sequence |
|
|
or |
or |
immediately.. Raccoon, |
|
|
HDCV 1 mL (IM) |
HDCV 1 mL (IM) |
skunk, bat, fox, and most |
|
|
in deltoid |
in deltoid on days |
wild carnivore bites should |
|
|
PCEC, RVA, |
0 and 3 |
be regarded as rabid, and |
|
|
|
bite victims should be |
|
|
|
HDCV given on |
|
|
|
|
|
vaccinated against rabies |
|
|
|
days 0, 3, 7, 14, |
|
|
|
|
|
immediately (contact |
|
|
|
and 28 post- |
|
|
|
|
|
local health department |
|
|
|
exposure |
|
|
|
|
|
regarding rabies potential |
|
|
|
|
|
|
|
|
|
|
of animals in your area).. All |
|
|
|
|
potential rabies wounds |
|
|
|
|
should immediately be |
|
|
|
|
thoroughly cleaned with |
|
|
|
|
soap and water.. Do not |
|
|
|
|
inject rabies vaccine IV |
|
|
|
|
(may cause hypotension/ |
|
|
|
|
shock).. Serum sickness may |
|
|
|
|
occur with HDCV.. |
|
|
|
|
|
HDCV = human diploid cell vaccine, HRIG = human rabies immune globulin, PCEC = purified chick embryo cells, RVA = rabies vaccine absorbed.
*All or as much of the full dose of HRIG should be injected into the wound, and the remaining vaccine should be injected IM into the deltoid.. Do not give HRIG at the same site or through the same syringe with PCEC, RVA, or HDCV..
|
Chapter 6. Prophylaxis and Immunizations |
363 |
||||
Table 6.3. Post-Exposure Prophylaxis (cont’d) |
|
|
|
|||
|
|
|
|
|
|
|
|
Usual |
Preferred |
Alternate |
|
||
Exposure |
Organisms |
Prophylaxis |
Prophylaxis |
Comments |
||
|
|
|
|
|
|
|
|
|
BIOTERRORIST AGENTS |
|
|||
|
|
|
|
|
|
|
Anthrax |
B.. anthracis |
Doxycycline |
|
Amoxicillin 1 gm |
|
Duration of anthrax |
Inhalation/ |
|
100 mg (PO) |
|
(PO) q8h × 60 |
|
PEP based on longest |
cutaneous |
|
q12h × 60 days |
|
days |
|
incubation period of |
|
|
or Ciprofloxacin |
|
|
|
inhaled spores in nares.. |
|
|
500 mg (PO) |
|
|
|
|
|
|
q12h × 60 days |
|
|
|
|
|
|
or Levofloxacin |
|
|
|
|
|
|
500 mg (PO) |
|
|
|
|
|
|
q24h × 60 days |
|
|
|
|
|
|
|
|
|
|
|
Tularemia |
F.. tularensis |
Doxycycline 100 |
|
Ciprofloxacin |
|
Duration of PEP for |
pneumonia |
|
mg (PO) q12h × |
|
500 mg (PO) |
|
tularemia is 2 weeks, not 1 |
|
|
2 weeks |
|
q12h × 2 weeks |
|
week as for plague.. |
|
|
|
|
or Levofloxacin |
|
|
|
|
|
|
500 mg (PO) |
|
|
|
|
|
|
q24h × 2 weeks |
|
|
|
|
|
|
|
|
|
Pneumonic |
Y.. pestis |
Doxycycline |
|
Chloramphenicol |
|
Pneumonic plague should |
plague |
|
100 mg (PO) |
|
500 mg (PO) q6h |
|
be considered bioterrorism |
|
|
q12h × 7 days |
|
× 7 days |
|
since most natural cases of |
|
|
or Ciprofloxacin |
|
|
|
plague are bubonic plague.. |
|
|
500 mg (PO) |
|
|
|
|
|
|
q12h × 7 days |
|
|
|
|
|
|
or Levofloxacin |
|
|
|
|
|
|
500 mg (PO) |
|
|
|
|
|
|
q24h × 7 days |
|
|
|
|
|
|
|
|
|
|
|
Smallpox |
Variola virus |
Smallpox |
|
None |
|
Smallpox vaccine is |
|
|
vaccine ≤4 days |
|
|
|
protective when diluted |
|
|
after exposure |
|
|
|
1:5.. |
|
|
|
|
|
|
|
Viral |
Lassa fever |
Ribavarin |
|
None |
|
Decrease maintenance |
hemorrhagic |
|
loading dose: |
|
|
|
dose to 7..5 mg/kg (PO) q8h |
fever |
|
35mg/kg (PO) |
|
|
|
if CrCl < 50/ml/min.. |
|
|
(not to exceed |
|
|
|
|
|
|
2..5 g), then 15 |
|
|
|
|
|
|
mg/kg (PO) (not |
|
|
|
|
|
|
to exceed 1g) |
|
|
|
|
|
|
q8h × |
|
|
|
|
|
|
10 days |
|
|
|
|
|
|
|
|
|
|
|